UMGCCC Clinical Trials

  • More About Clinical Trials
  • Deciding to Enroll
  • Questions to Ask
  • For More Information
  • Research
  • Cancer Overviews
  • Treatment Programs
  • Physicians and Staff
Protocol SummaryBack To Search Instructions
Protocol No.NRG-BN001Principal InvestigatorMishra, Mark
PhasePhase II (Cancer Control)
Age GroupAdult
TitleRANDOMIZED PHASE II TRIAL OF HYPOFRACTIONATED DOSE-ESCALATED PHOTON IMRT OR PROTON BEAM THERAPY VERSUS CONVENTIONAL PHOTON IRRADIATION WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Treatment Radiation: 3-dimensional conformal radiation therapy; intensity-modulated radiation ; proton beam radiation therapy Drug: temozolomide
Key EligibilityInclusion Criteria STEP 1:

1. A diagnostic contrast-enhanced MRI (no other scan type allowed) of the brain must be performed postoperative.
2. Tumor tissue must be available for submission for central pathology review.
3. The tumor must be located in the supratentorial compartment only (any component involving the brain stem or cerebellum is not allowed).
4. Patients must provide study-specific informed consent prior to step 1 registration.

Inclusion Criteria STEP 2:

5. Histologically proven diagnosis of glioblastoma (WHO grade IV) confirmed by central review prior to step 2 registration.
6. Tumor tissue that is determined by central pathology review prior to step 2 registration to be of sufficient quantity for analysis of MGMT status.
7. History/physical examination within 28 days prior to step 2 registration.
8. The patient must have recovered from effects of surgery, postoperative infection, and other complications within 28 days prior to step 2 registration.
9. Documentation of steroid doses within 28 days prior to step 2 registration.
10. Karnofsky performance status greater than or equal to 70 within 28 days prior to step 2 registration.
11. Age greater than or equal to 18.
12. CBC/differential obtained within 28 days prior to step 2 registration, with adequate bone marrow function.
13. Adequate hepatic function within 28 days prior to step 2 registration.
14. Negative serum pregnancy test obtained for females of child-bearing potential within 28 days prior to step 2 registration.


*For exclusion criteria information please, call study site contact.*





Applicable Disease SitesBrain and Nervous System
Therapies InvolvedRadiotherapy
Drugs InvolvedTemozolomide
StatusOpen
Treatment TypeTreatment
ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02179086
ContactGreenebaum Cancer Center Caroline Poff, MS, R.N. Phone:410-369-5264
Pager:
Email:CAROLINE.POFF@umm.edu
Back to Protocol Listing